Archive · 1 Aug 2025
GSK Pharma to Launch Oncology Assets, Reports Financials
GSK Pharma is preparing to launch two cancer-fighting drugs called Jemperli and Zejula in India.
The company's boss says they will invest in new products.
The goal is to help people with cancer since this disease is becoming more common.
GSK made a good amount of money in the last few months.
The vaccines that they make, especially for adults, are also doing well, while overall growth was flat for the quarter.
GSK Pharma is on track to launch its oncology assets Jemperli and Zejula.
The company will invest in its innovative portfolio, according to the Managing Director.
GSK aims to address the rising cancer burden in India.
Revenue from operations for the quarter was Rs 805 crores, with a PAT of Rs 205 crores.
The company's vaccines business is performing well, particularly adult vaccines.
- Who
- GlaxoSmithKline Pharmaceuticals.
- What
- GSK Pharma is launching oncology assets Jemperli and Zejula.
- When
- The company's financial performance was announced for the three months ended June 30, 2025. The article was published on August 1, 2025.
- Where
- India.
- Why
- To address the rising cancer burden and provide advanced therapies in India.
- Company
- GlaxoSmithKline Pharmaceuticals
- Managing Director
- Bhushan Akshikar
- Oncology Assets
- Jemperli and Zejula
- Revenue from Operations
- Rs 805 crores
- Profit After Tax (PAT)
- Rs 205 crores